Ovarian Cancer

Surgery followed by platinum-based chemotherapy may provide the most benefit for patients with ovarian cancer, according to a medical oncologist.

Ovarian cancer decedents who received early palliative care had improved quality and less aggressive end-of-life care.

An FDA filing decision is anticipated before the end of 2024 for avutometinib/defactinib in recurrent KRAS-mutant low-grade serous ovarian cancer.

Updated findings from RAMP 201 show that avutometinib/defactinib is generally well tolerated among those with low-grade serous ovarian cancer.

Combining IMNN-001 with chemotherapy also elicited a progression-free survival improvement compared with chemotherapy alone in the OVATION 2 trial.

A ready-to-dilute formula of SH-105 has been approved by the FDA to treat breast and ovarian cancers.

There was no benefit derived from adding atezolizumab to chemotherapy and bevacizumab in patients with recurrent ovarian cancer.

A survival benefit was observed when nivolumab and ipilimumab were combined to treat ovarian or gynecologic clear cell carcinoma.

Data from the phase 2 RAMP 201 trial may support the potential accelerated approval of avutometinib/defactinib in KRAS-mutated LGSOC.

Findings may support reconsideration of guideline recommendations concerning the use of estrogen alone in postmenopausal individuals.

Fumiko Chino, MD, discusses how recent findings of talcum powder use were linked to ovarian cancer.

Results of the Sister Study cohort found an increased risk of ovarian cancer when enrolled patients used genital talcum powder throughout young adulthood.

Although the sample size for this trial was small, data still highlight a potential benefit with nivolumab in dMMR uterine and ovarian cancers.

Combining rintatolimod with pembrolizumab may confer a synergistic effect in patients with recurrent ovarian cancer.

A phase 1b evaluating NXP800 in platinum-resistant ARID1A-mutated ovarian cancer is open for enrollment in the United Kingdom and the United States.

Even when adjusting for prior taxane responses in patients with ovarian cancer, ixabepilone/bevacizumab appears to yield survival benefits in a phase 2 trial.

Findings from the phase 2 RAMP 201 trial highlight responses with avutometinib/defactinib in those with KRAS-mutated low-grade serous ovarian cancer and other patient subgroups.

Several patients with TP53 Y220C–mutated ovarian cancer experience tumor shrinkage following treatment with rezatapopt in the phase 1/2 PYNNACLE study.

Data from the phase 3 MIRASOL trial support the full FDA approval of mirvetuximab soravtansine for those with folate receptor alpha–positive platinum-resistant ovarian cancer.

Ex vivo generation of CD3-positive, CD56-positive Natural Killer-Like (NKT) with CRX100 was successful in all 7 patients with ovarian cancer in a phase 1 trial.

Patient reported outcomes from the phase 3 MIRASOL trial showed improvement when mirvetuximab was used vs standard of care in folate receptor-alpha positive ovarian cancer resistant ovarian cancer.

The phase 2/3 NRG-GY005 trial assessing olaparib plus dediranib did not improve survival vs standard of care in ovarian cancer.

Investigators are assessing avutometinib plus defactinib as a treatment for those with low-grade serous ovarian cancer as part of the phase 3 RAMP 301 trial.

We present the case of a 51-year-old woman with metastatic International FIGO stage IIIC ovarian cancer who had delayed her therapy after initial laparoscopy due to COVID-19 infection and presented with an extreme case of surgical port metastasis.

Patients with advanced ovarian cancer who received primary or interval cytoreduction surgery experienced higher rates of overall and progression-free survival.